1 / 19

ITMO Cancer

ITMO Cancer. From Precision to Personalised Medicine Brussels 24/09/2013. CEA. CHRU. CNRS. CPU. INRA. INRIA. INSERM. INSTITUT PASTEUR. IRD. ARIIS. CIRAD. EFS. FONDATION MERIEUX. INERIS. INSTITUT CURIE. INSTITUT MINES-TELECOM. IRBA. IRSN. UNICANCER.

farrah
Télécharger la présentation

ITMO Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ITMO Cancer From Precision to Personalised Medicine Brussels24/09/2013 CEA CHRU CNRS CPU INRA INRIA INSERM INSTITUT PASTEUR IRD ARIIS CIRAD EFS FONDATION MERIEUX INERIS INSTITUT CURIE INSTITUT MINES-TELECOM IRBA IRSN UNICANCER

  2. Genomics in Oncology: from biology to care • Generating information about cancer development and metastasis • Identifying new genes susceptible to induce « addiction », thus « targetable » • Helping to develop new therapies • Helping to accelerate new drug approval: new early phase trials, shortening time to MA

  3. How are we currently using genomics in patient management?

  4. Structures and Infrastructures: Molecular genetic centers • High quality molecular testing, all patients, anywhere in France • PartnershipsbetweenUniversityhospitals and cancer centers • Regionalorganization • PPPswith Roche, Amgen, Pfizer, GSK, AZ

  5. From genetic centers to biology driven therapy F Nowak, JC Soria and F Calvo, Nat Rev Clin Oncol. 2012

  6. An increasing number of actionable molecular alterations • Implementation of Next Generation Sequencing (NGS) for clinical use • Development of pharmacogenetics for reducing toxicities and improving efficacy • Implementation ongoing for the investigation of a panel of genes • Next years : analysis of whole exome or genome

  7. Single genes Gene panels Exomes Whole genomes • Gene expression profiles • Copy Number Variation 2000 2010 2015 • New technologies… have resulted in > 100,000-fold decreases in sequencing costs: • $1,000/genome will soon be achieved

  8. ICGC Map 64 projects launched

  9. ICGC: Liver Cancer genome programme Guichard et al. Nature Genetics, 2012

  10. Proof of concept for molecularly guided therapy: prospective trial for the future • Need to demonstrate that sequencing tumours (Exome-Whole GS) is of interest for treatment decision • A national cooperative randomized study in early metastatic patient in some tumour types • Comparing therapeutic decision based on NGS to current diagnostic procedures including defined genetic tests • To be performed in the CLIP2 (INCa- Fondation ARC- Unicancer) • With the help of Pharmas to provide drugs already in phase 2 trials

  11. Conclusionsand perspectives The French molecular screening initiative : • has been operational for 5 years for access to targeted therapies • Opens the path to switch to complete genomics and personalized therapy • is an opportunity to improve patient accrual into clinical trials Current research on genomics of cancer • is the basis to understand the steps of cancer development, identify new targets and develop new therapies through the synergy between fundamental, translational and clinical sciences • Allows to foster on innovation through bioinformatics, biomarkers and drug development

  12. Rapid access to innovation Offer each patient in France an equal access to molecular tests as soon as a new targeted therapy is available Mid 2008 : EMA approvals for panitumumab and cetuximab for patients with wild type KRAS tumours • Allocation of €2.5M to the 28 centres at the end of 2008 June 2009 :gefitinib approvals by EMA for patients with activating mutations of EGFR in their tumors • Allocation of €1.7M to the 28 centres at the end of 2009

  13. Surveys of mutation databases indicate that most mutations are found in many tumour types Sanger Institute: http://www.sanger.ac.uk/cosmic, COSMIC v54 Release (Forbes et al., 2011).

  14. Targeted therapies with sufficient preclinical and clinical data (level 1) Targetedtherapy PIK3CA mutations (1%) TSC1 and TSC2 mutations (7%) PTEN HD (2%) Activation without known mutation (10%) Activation of AKT/mTor pathway (20%) mTor inhibitor(everolimus, sirolimus) Activation of ras/raf/MAP kinase pathway (9 %) BRAF V600 inhibitor (vemurafenib) BRAF mutation (1%) FGFR inhibitor (pazopanib) FGF19 amplification (1%) EGFR overexpression (1%) HER2neu overexpression(1%) Cytokine and growth factor receptors (7%) Antibody anti-EGFR (cetuximab) Antibody anti-HER2 (trastuzumab) SUFU mutation (1 %) MGMT HD (1%) Inhibitor of sonic hedgehog(vismodegib) Private mutations (2%) Oral alkylating agent (temozolomid) Courtesy of Nault and Zucman, unpublished

  15. Putative targeted therapies: on-going pre-clinical analyses (level 2) Targetedtherapy NFE2L2 mutation (5%) KEAP1 mutation (3%) Activation without known mutation (12%) HSP90 inhibitor (17-AAG and 17-DMAG) Activation of NFE2L2/KEAP1 pathway (20 %) MEK 1/2 inhibitor (selumitinib) Activation of ras/raf/MAP kinase pathway (9 %) RPS6KA3 mutation (8%) JAK1/JAK2 inhibitor (ruxolitinib) Cytokine and growth factor receptors (7 %) IL6ST mutation (2%) Courtesy of Nault and Zucman, unpublished

  16. SAFIR02 BiopsyMetastatic Site: NGS targetgenesequencing Arm A: targeted therapy According to the molecular alteration R Druggable molecular alteration Arm B: best availabletherapy Based on available mono-test Metastatic Her2-neg breast cancer pretreatedwith 1 line chemotherapy Metastatic EGFR / ALK wtlung cancer not pretreatedwithchemotherapy Chemotherapy: 6-8 cycles PR, SD PI: Fabrice André Sponsor: UNICANCER- Fundingpartners INCa-ARC N: 1000 for screening, 400 for therapeutic phase No alteration Or non druggable Not included

  17. 2012 data 36,4% 3,9%

  18. Liver Cancer genome programme Guichard et al. Nature Genetics, 2012

More Related